Comprehensive medication guide to Elahere including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Costs vary widely by plan. Commercial insurance patients may pay as little as $0/cycle with the ELAHERE Support Services co-pay card. Medicare Part B patients face 20% coinsurance (no cap without supplemental coverage). Prior authorization is almost universally required.
Estimated Cash Pricing
~$29,307 per treatment cycle at list price; a single 100 mg/20 mL vial starts at approximately $6,715. No generic available. Billed through medical benefit, not pharmacy benefit.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Elahere (mirvetuximab soravtansine-gynx) is a first-in-class antibody-drug conjugate (ADC) manufactured by AbbVie. The FDA granted accelerated approval on November 14, 2022, and full approval on March 22, 2024. It is indicated for adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
Elahere is the first ADC approved for platinum-resistant ovarian cancer and the first therapy ever to demonstrate an overall survival benefit in this setting. It is not a pill — it is administered as an intravenous (IV) infusion at an oncology infusion center, 6 mg/kg (adjusted ideal body weight) every 3 weeks. Patients must be confirmed FRα-positive via the VENTANA FOLR1 (FOLR-2.1) RxDx Assay companion diagnostic before beginning treatment.
In the Phase 3 MIRASOL trial, Elahere achieved a median overall survival of 16.5 months versus 12.7 months for standard chemotherapy (HR 0.67; p=0.0046), with an objective response rate of 42.3% vs 15.9%.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Elahere is an antibody-drug conjugate consisting of three components: (1) mirvetuximab, a monoclonal antibody (IgG1 subtype) that targets folate receptor alpha (FRα) on cancer cell surfaces; (2) a cleavable sulfo-SPDB linker; and (3) DM4, a potent maytansinoid tubulin inhibitor (average drug-to-antibody ratio of 3.4). FRα is overexpressed on approximately 80% of high-grade serous ovarian cancers but is minimally expressed on most normal tissues, making it an ideal therapeutic target.
After IV administration, mirvetuximab circulates through the bloodstream and binds to FRα on the surface of ovarian cancer cells. The cancer cell then internalizes the entire ADC complex via receptor-mediated endocytosis. Inside the cell, the acidic lysosomal environment cleaves the linker, releasing DM4. DM4 disrupts microtubule assembly by binding to tubulin, causing mitotic arrest and cancer cell death.
This targeted delivery mechanism spares most healthy cells from the cytotoxic effects of DM4, resulting in a different and often more tolerable side effect profile compared to conventional chemotherapy. The primary toxicities arise because FRα is also expressed at low levels in ocular tissues, leading to Elahere's boxed warning for ocular toxicity.
6 mg/kg AIBW — IV infusion (100 mg/20 mL vial)
Administered once every 3 weeks (Day 1 of a 21-day cycle) until disease progression or unacceptable toxicity. Dose based on adjusted ideal body weight (AIBW), not actual body weight.
Elahere is not on the FDA Drug Shortage Database as of 2026. However, it is not available at retail pharmacies and can only be obtained through specialty oncology infusion centers. Patients face significant access challenges related to insurance prior authorization (typically 2-4 weeks), companion diagnostic testing requirements (VENTANA FOLR1 assay), and the specialty distribution system. Geographic disparities also exist — patients in rural areas may face longer travel times to reach facilities that administer Elahere.
Finding an infusion center that stocks and administers Elahere can be time-consuming. medfinder is a paid service that calls facilities near you to identify which ones can fill your Elahere prescription — saving you from making dozens of calls during an already stressful time.
The ELAHERE Support Services program (1-833-352-4373) also offers dedicated Case Managers who specialize in insurance navigation and locating specialty infusion centers.
Elahere is not a controlled substance and has no DEA scheduling requirements. However, it is a specialty oncology biologic that must be prescribed by a licensed healthcare provider with oncology experience, access to companion diagnostic testing (VENTANA FOLR1 assay), and an affiliated infusion center capable of administering IV biologics and providing ophthalmic monitoring.
Gynecologic oncologists — primary prescribers; sub-specialists in female reproductive system cancers
Medical oncologists — particularly those at cancer centers with gynecologic oncology programs
Nurse Practitioners (NPs) and Physician Assistants (PAs) — can prescribe Elahere in oncology practices under physician supervision
Telehealth consultations with gynecologic oncologists are available for initial evaluation and treatment planning, but Elahere infusions must always be administered in-person at a qualified oncology infusion center. Use the NCI Cancer Center Finder at cancer.gov or the SGO member directory at sgo.org to locate a qualified prescriber near you.
No. Elahere (mirvetuximab soravtansine-gynx) is not a controlled substance and is not scheduled by the DEA. There are no DEA scheduling restrictions, and it does not require a DEA-compliant prescription or specific prescription refill limitations based on controlled substance schedules.
However, Elahere is a specialty biologic that must be prescribed by a licensed healthcare provider experienced in oncology and administered by trained healthcare professionals at qualified infusion centers. Access requires companion diagnostic testing, insurance prior authorization, and careful monitoring protocols — including mandatory ophthalmic monitoring for its boxed-warning ocular toxicity.
In the Phase 3 MIRASOL trial, the most common side effects (occurring in ≥10% of patients) included:
Fatigue (47%)
Blurred vision (45%)
Keratopathy/cornea damage (37%)
Peripheral neuropathy (37%)
Abdominal pain (34%)
Musculoskeletal pain (31%)
Dry eye (29%), diarrhea (29%), nausea (27%), constipation (27%)
Pneumonitis (10%)
Severe ocular toxicity (boxed warning): keratopathy Grade 3+ in 11%, blurred vision Grade 3+ in 9% — requires mandatory eye monitoring
ILD/Pneumonitis: potentially life-threatening lung inflammation; monitor for new/worsening dyspnea
Embryo-fetal toxicity: contains genotoxic DM4; contraindicated in pregnancy
Infusion-related reactions: occur in ~8% of patients; premedication required
Know what you need? Skip the search.
Paclitaxel (Taxol)
Weekly IV taxane chemotherapy; ORR ~10-13% as single agent in platinum-resistant OC; one of the standard IC regimens; widely available as generic.
Pegylated Liposomal Doxorubicin (Doxil/PLD)
IV anthracycline given every 4 weeks; ORR ~10-13%; less hair loss than conventional doxorubicin; has a history of intermittent supply shortages.
Topotecan (Hycamtin)
IV topoisomerase I inhibitor; significant myelosuppression; ORR ~10-13%; available as generic; can be given IV or orally.
Bevacizumab (Avastin)
Anti-VEGF monoclonal antibody often added to chemotherapy (paclitaxel, PLD, or topotecan); AURELIA trial showed improved PFS to 6.7 months; does not require FRα testing; no OS benefit shown in PROC.
Relacorilant (Lifyorli)
FDA-approved March 2026 in combination with nab-paclitaxel for platinum-resistant OC; biomarker-agnostic (no FRα test needed); first-in-class selective glucocorticoid receptor antagonist.
Prefer Elahere? We can find it.
Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, atazanavir, darunavir)
moderateMay increase unconjugated DM4 (CYP3A4 substrate) exposure, increasing toxicity risk including ocular and neurological adverse reactions. Use caution and monitor closely.
Strong CYP3A4 Inducers (rifampin, phenytoin, carbamazepine, St. John's Wort)
moderateMay decrease DM4 exposure, potentially reducing Elahere's efficacy. Avoid concurrent use when possible.
Etrasimod (Velsipity)
majorAdditive immunosuppressive effects; risk of serious infection. Avoid coadministration during and in the weeks following etrasimod administration.
Elahere represents a landmark advance in the treatment of platinum-resistant ovarian cancer — the first therapy ever to demonstrate an overall survival benefit in this challenging setting. For FRα-positive patients, the MIRASOL trial data are compelling: a 33% reduction in the risk of death, a more-than-doubling of objective response rate compared to standard chemotherapy, and a more tolerable side effect profile that preserves quality of life. The unique eye toxicity profile requires proactive ophthalmology coordination but is generally manageable.
The main challenges in 2026 are access-related: insurance prior authorization, companion diagnostic testing, and the specialty distribution system. Early FRα testing and enrollment in AbbVie's ELAHERE Support Services program are the most important steps patients and providers can take to avoid treatment delays. Financial assistance is available for both commercially insured patients (co-pay card) and uninsured/underinsured patients (Patient Assistance Program).
If you're struggling to find an infusion center that administers Elahere in your area, medfinder is a paid service that calls facilities near you to identify those that can fill your prescription — saving you time and stress during a difficult period.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini